Hikma launches version of Xyrem medicine in US for treating narcolepsy - Marketscreener.com

1 year ago 74

(Alliance News) - Hikma Pharmaceuticals PLC connected Tuesday said it launched an authorised generic mentation of the Xyrem sodium oxybate medicine medicine successful the US for treating narcolepsy.

The London-based pharmaceutical institution said its mentation is based connected Jazz Pharmaceuticals' Xyrem oral solution CIII and volition beryllium utilized to dainty symptoms of excessive daytime sleepiness and abrupt onset of anemic oregon paralysed muscles, different known arsenic cataplexy.

Hikma volition person 180 days of selling exclusivity for its authorised generic merchandise successful the US.

It cited Jazz Pharmaceuticals reported nett income for Xyrem of astir USD1.3 cardinal successful 2021.

"We are pleased to beryllium capable to supply the archetypal authorised generic mentation of Xyrem to patients and wellness attraction providers successful the US. This motorboat further expands our diversified portfolio of generic products, and underscores our quality to enactment 'Better Health, Within Reach, Every Day' for the millions of radical who trust connected our medicines," said Brian Hoffmann, Hikma's president of generics.

Shares successful Hikma were up 5.6% to 1,639.00 pence each successful London connected Tuesday morning.

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Read Entire Article